[Clinical development of targeted moledular cancer drugs].
Zwierzina
Heinz
H
Medizinische Klinik, Universitätsklinik Innsbruck, Innsbruck, Austria.
Borner
Markus
M
D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D014408:Biomarkers, Tumor / Q000235:genetics*; D002986:Clinical Trials as Topic; D020732:Cytogenetic Analysis; D016503:Drug Delivery Systems; D066246:ErbB Receptors / Q000037:antagonists & inhibitors / Q000235:genetics; D006801:Humans; D009369:Neoplasms / Q000188:drug therapy* / Q000235:genetics* / Q000401:mortality; D011505:Protein-Tyrosine Kinases / Q000037:antagonists & inhibitors / Q000235:genetics; D015996:Survival Rate
D000911:Antibodies, Monoclonal; D014408:Biomarkers, Tumor; D066246:ErbB Receptors; D011505:Protein-Tyrosine Kinases